The global idiopathic pulmonary fibrosis management market is expected to garner a market value of USD 3145 Million in 2023 and is expected to accumulate a market value of USD 3649.90 Million by registering a CAGR of 1.5% in the forecast period 2023 to 2033.
The growth of the idiopathic pulmonary fibrosis management market can be attributed to the increasing prevalence of the ailment in males across the globe. The market for idiopathic pulmonary fibrosis management registered a CAGR of 1% in the historical period 2018 to 2022
Idiopathic pulmonary fibrosis (IPF) is a lung disorder with scarring of the lungs from an unknown cause. It is one of the most aggressive forms of idiopathic interstitial pneumonia (IIPs). The majority of patients are male, and the risk of IPF for someone aged 75 years is eight times that of someone aged 45 to 54 years.
It is reported that without treatment, the median survival in patients with IPF is 2 to 4 years after diagnosis. Males are more predominantly affected highly with IPF than females. In 2021, there were 121,389 males and 73,488 females affected by IPF in the 7MM.
There are two antifibrotic agents approved for use in IPF. These are pirfenidone and nintedanib (tyrosine kinase inhibitors). Both drugs are known to slow the disease progression but not significantly impact mortality. For this reason, early initiation of therapy is recommended.
Further studies have also decreased exacerbations of IPF with these drugs. Serial monitoring of liver function tests is recommended while on either drug. The most common side effect reported with nintedanib is diarrhea and pirfenidone rash, photosensitivity, and gastrointestinal discomfort.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 3145 Million |
| Anticipated Forecast Value (2033) | USD 3649.90 Million |
| Projected Growth Rate (2023 to 2033) | 1.5% CAGR |
Explore FMI!
Book a free demo
According to market research and competitive intelligence provider Future Market Insights - the market for Idiopathic pulmonary fibrosis management reflected a value of 1% during the historical period, 2018 to 2022.
The total diagnosed prevalent cases of Idiopathic Pulmonary Fibrosis in the 7MM was 194,878 cases in 2021. Gastrointestinal side effects are the most common reason for discontinuing both drugs. According to survey reports, most European physicians are either unaware of these antifibrotic drugs or believe in the wait-and-watch strategies during the progression of IPF. It was found that only 71% of mild IPF-diagnosed patients, 41% of moderate IPF-diagnosed patients, and around 60% of severe IPF-diagnosed patients receive treatment in European counties.
Over the years, some drugs have been investigated to treat IPF cases. Drug molecules such as Pamrevlumab, PRM-151, and Inhaled Treprostinil are in Phase III and have shown positive results in previous clinical studies. In addition to this, some candidates are in Phase II and early stages. Thus, the market for Idiopathic pulmonary fibrosis management is expected to register a CAGR of 1.5% in the forecast period 2023 to 2033.
Increasing prevalence of Idiopathic pulmonary fibrosis in middle-aged men boosting the market growth
Idiopathic Pulmonary Fibrosis (IPF) is a rare, chronic, progressive fibrosing interstitial pneumonia that is found to affect middle to aged and older adults. It affects lung tissue (alveoli in particular) by either thickening, stiffening, or persistent and progressive scarring (fibrosis), which increases irreversibly over time.
If an individual has IPF, scarring affects the air sacs, limiting the amount of oxygen that gets into the blood. With less oxygen in the blood, one can get breathlessness from everyday activities, like walking. This group of lung disorders is also known as ‘Diffuse Parenchymal Lung Diseases,’ which is characterized by a broader umbrella of ‘Interstitial Lung Diseases (IDLs).
It is a form of interstitial lung disease, primarily involving the interstitium (the tissue and space around the air sacs of the lungs) and not directly affecting the airways or blood vessels. Many other kinds of interstitial lung disease can also cause inflammation and/or fibrosis, and these are treated differently.
Availability of various diagnostic treatments spurring the growth of Idiopathic pulmonary fibrosis management
There are several diagnostic tools available and the consensus guidelines have been well-defined to identify IPF. Pulmonary function tests are performed to assess for restrictive lung disease which is characterized by decreased lung volumes (especially decreased forced vital capacity, total lung capacity, and functional residual capacity) and decreased diffusion capacity.
When IPF is suspected, laboratory tests to exclude autoimmune disease are also performed. Chest imaging is like XtoRays is done but when they are not detailed enough to confirm IPF. High-resolution CT (HRCT) of the chest is performed. Patients may also be referred to a surgeon for a lung biopsy under general anesthesia in some instances.
Careful evaluation of clinical, laboratory, Xtoray data and high resolution computed tomography (HRCT), and at times lung biopsy material to make a confident diagnosis. This is usually done by a respiratory specialist in union with other specialists with an interest in IPF. The diagnosis of IPF relies on the clinician to assimilate and correlate the clinical, laboratory, radiologic, and/or pathology data.
The therapeutic approach to Idiopathic Pulmonary Fibrosis involves both non-pharmacological and pharmacological strategies. The goal of the treatment is to slow disease progression, reduce symptoms, prevent acute exacerbations, and prolong survival. There are two anti-fibrotic agents ESBRIET (Roche) and OFEV (Boehringer Ingelheim) approved for use in IPF. Both drugs are known to slow the disease progression but do not significantly impact mortality.
Lack of awareness and high cost of treatment affecting the market growth
Difficulty in diagnosis is a key factor hindering the growth of the market. As IPF often mimics other lung diseases, making it difficult to diagnose. This can lead to delayed treatment and a poorer prognosis. Furthermore, limited treatment options and no assurance of results are derailing the growth of the market.
In addition, lack of awareness of IPF as it is a rare disease. This can make it difficult for patients to find doctors who are familiar with the disease and can lead to a delay in diagnosis and treatment. Moreover, the high cost of treatment is a burden for patients and their families. All these factors are creating obstacles to the growth of the market.
High market penetration and increasing prices of the drugs are other factors driving the growth of the market
The highest diagnosed prevalent cases of IPF were accounted for by the USA in 2021, with 94,736 cases in the 7MM, which is expected to show a steep rise soon due to the improvement in diagnostic testing and increasing population. Owing to high market penetration and increasing prices of the drugs are other factors driving the growth of the market.
The market is growing rapidly due to accelerated approvals of two drugs in the United States of America. Moreover, the increasing prevalence of IPF is one of the major factors anticipated to boost the market.
Manufacturers offer various programs to improve access among patients. For instance, F. Hoffman La-Roche, Ltd (Genentech) offers Genentech Access to Care Foundation and Esbriet Co-Pay Card Program that covers out-of-pocket expenses and provides Esbriet free of charge for certain household income thresholds.
Boehringer Ingelheim offers similar free access and co-pay assistance programs. Thus, North America is expected to possess a 45% market share for the Idiopathic pulmonary fibrosis management market in 2023.
Launch of innovative medications supporting idiopathic pulmonary fibrosis management market growth in Europe
Europe was estimated to be the second-largest market in 2022 owing to the increasing prevalence of IPF. For instance, according to the European Idiopathic Pulmonary Fibrosis Foundation, 30,000 to 35,000 new cases of IPF are diagnosed every year. Moreover, between 80,000 to 111,000 people are living with IPF in Europe. The average life expectancy of patients diagnosed with IPF is 2-5 years.
Among the European countries, Germany had the highest diagnosed prevalent population of IPF with 20,774 cases, followed by the UK with 15,760 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population. In addition, improved healthcare infrastructure along with the availability of innovative medications is expected to drive the growth of the market. Thus, Europe is expected to hold a 40% market share of the Idiopathic pulmonary fibrosis management market in 2023.
Easy purchase of multiple medicines increasing the popularity of retail pharmacies
The availability of both prescription and over-the-counter drugs in retail pharmacies is driving growth in the pulmonary fibrosis treatment market and is expected to continue doing so in the future. This, in turn, makes it convenient for consumers to fill multiple prescriptions and purchase other healthcare products all in one place.
This increase in convenience and access to healthcare services is likely a major factor in the growing popularity of retail pharmacies. Thus, retail pharmacies are expected to possess a 40% market share of the Idiopathic pulmonary fibrosis management market in 2023.
Key players in the idiopathic pulmonary fibrosis management market are Boehringer Ingelheim GMBH, Biogen, Novartis AG, Medicinova Inc, Bristol Myers Squibb Company, Galapagos NV, HoffmanntoLa Roche AG, Neopharm Group, Galecto Biotech, Pfizer Inc, Johnson & Johnson Services, Inc, AstraZeneca
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3145 Million |
| Market Value in 2033 | USD 3649.90 Million |
| Growth Rate | CAGR of 1.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Treatment, Route of Administration, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa |
| Key Countries Profiled | USA, Canada, Brazil, Argentina, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASIAN, GCC Countries, South Africa |
| Key Companies Profiled | Boehringer Ingelheim GMBH; Biogen; Novartis AG; Medicinova Inc; Bristol Myers Squibb Company; Galapagos NV; Hoffmann-La Roche AG; Neopharm Group; Galecto Biotech; Pfizer Inc; Johnson & Johnson Services, Inc; AstraZeneca |
| Customization | Available Upon Request |
The United States generated 40% of the global demand in 2022.
The Asia Pacific market is expected to grow at 9.4% through 2033.
The small molecule drugs segment contributes 60% of total production.
The oral segment holds 55% of the global market share.
From 2018 to 2022, the global market exhibited a CAGR of 1%.
Healthcare Biometrics Market Trends - Growth, Demand & Forecast 2025 to 2035
Healthcare API Market Growth – Trends & Forecast 2025 to 2035
Gastrointestinal Stent Market Growth – Trends & Forecast 2025 to 2035
Gel Implants Market Analysis - Trends, Share & Forecast 2025 to 2035
3D Printing Dental Devices Market Growth - Trends & Forecast 2025 to 2035
3D Printed Hip and Knee Implants Market Growth - Trends & Forecast 2025 to 2035
Idiopathic Pulmonary Fibrosis Management Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
